The Global Respiratory Syncytial Virus Therapeutics market is expected to grow from 2018 to 2026.
Oct 9, 2019
The key vendors mentioned are MEDIVIR AB, AstraZeneca plc., AbbVie, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Teva Pharmaceuticals Industries Ltd., Merck Co., Inc., GlaxoSmithKline plc., ReViral Ltd., and Valeant Pharmaceuticals International, Inc.
Hyderabad, India - October 9, 2019 /MarketersMedia/ —
Respiratory syncytial virus (RSV) is a common and contagious virus that infects the respiratory tract of children and adults. An RSV infection can lead to serious problems such as bronchiolitis and pneumonia. RSV is spread from respiratory secretions through close contact with infected persons. RSV does not usually occur until a baby is 4 to 6 week old. No specific approved drug or vaccine has been available to treat or prevent RSV infection to date. Factors such as Rise in prevalence of RSV infection among infants and the increasing interest of different biotechnology companies to develop various recombinant drugs to treat RSV infection are fuelling the market growth. However, the high price of prophylaxis drugs and a lack of return of investment in antiviral drugs are anticipated to restrict the market growth.
Access the complete report at: https://www.syngeneresearch.com/global-respiratory-syncytial-virus-therapeutics-market-analysis-2019-2/
By dosage form, the injectable segment is going to have a lucrative growth during the forecast period as it provides instant response to treat or prevent RSV infection. For example, AstraZeneca has developed a monoclonal antibody, called SYNAGIS, to prevent severe RSV infection, which is available in the injectable form. The advantage of this injection is that it instantly boosts the immune system to combat the infection.
Make an inquiry at: https://www.syngeneresearch.com/global-respiratory-syncytial-virus-therapeutics-market-analysis-2019-2/
Dosage Forms Covered:
• Injectable
• Oral
• Other Dosage Forms
Drugs Types Covered:
• Ribavirin
• Palivizumab
• Other Drugs Types
Distribution Channels Covered:
• Hospital Pharmacies
• Drug Stores
• Retail Pharmacies
• Other Distribution Channels
Regions Covered:
• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa
Learn more about Syngeneresearch here: https://www.syngeneresearch.com/about-syngene-research/
Key Questions Answered in this Report:
• How this market evolved since the year 2016
• Market size estimations, forecasts and CAGR for all the segments presented in the scope
• Key Market Developments and financials of the key players
• Opportunity Analysis for the new entrants
• SWOT Analysis of the key players
• Fastest growing markets analysed during the forecast period
Contact Info:
Name: Sadhana Shukla
Email: Send Email
Organization: Syngene Market Research Reports
Website: https://www.syngeneresearch.com/
Source: MarketersMedia
Release ID: 88926727
More News
EV boom zaps second-hand prices for petrol and diesel cars
As Australian drivers upgrade to EVs, they’re offloading their old fuel-reliant cars en masse – and prices are falling rapidly.
‘China Shock 2.0’ is coming and the world is on edge
You may think you have lived through an enormous economic shock as the result of the rise of China. But you ain’t seen nothing yet.
Big Hits: Haranga delivers US Mother Lode gold masterclass
Big Hits looks at notable drill intercepts reported to the ASX this week, led by Haranga Resources in California, which breathed new life into the historic Mother Lode Gold Belt.
ASX Runners of the Week: Identifai, Avenira & Image Resources
This week’s Bulls N’ Bears ASX Runner of the Week is… Identifai, after the Israeli biotech newcomer made a stellar debut on the ASX with its AI-powered prenatal screening technology.
Aurum hits more golden paydirt beyond West African resource
Aurum has hit bonanza gold, including 0.65m at 41.38g/t, outside its BST1 resource at the 3.22Moz Boundiali project, ahead of a key gold resource update due this month.
Forrestania fast-tracks WA gold production for December
Forrestania is fast-tracking its Edna May gold restart for December. First ore is on the pad, mill liners are en route, and mining has mobilised.
December rare earths production debut looms for Lindian in Malawi
Lindian Resources is set for first rare earths production in December at its Kangankunde project in Malawi, with construction and power infrastructure nearly complete.
Miners and tech stocks rally, taking ASX to third week of gains
The Australian sharemarket has clocked a third straight positive week despite a brutal mid-week sell-down, as investors grapple with fast-moving market risks.
Dating apps are supposed to make money and help people find love. Are they doing neither?
“The worst thing possible for Hinge is for people to fall in love,” says Australian writer Alistair Kitchen, who has created his own app to rival it.
TVSN fires off legal letters as war with suppliers escalates
TVSN director Bernie Brookes is refusing to hand the business over to administrators as suppliers become infuriated with the home shopping network’s radio silence.
McKinsey leader steps down from charity board after controversial ‘glass cliff’ comments
Chris Bradley resigned from Opportunity International Australia just days after his controversial remarks about the challenges female CEOs face.
The three factors driving NSW unemployment to a five-year high
The NSW unemployment rate hit 4.7 per cent last month, the highest level since November 2021.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.